Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.

Nocturnal asthma-like symptoms tied to obstructive sleep apnoea risk

01 Dec 2019

Symptoms of obstructive sleep apnoea (OSA) are similar to some nocturnal asthma-like symptoms (NAS), suggests a recent study.

“OSA and asthma are associated, and nocturnal breathing difficulty that is usually identified as asthma-like symptoms can be present in both conditions,” the authors said.

This study examined how NAS and bronchial hyper-reactivity (BHR) contributed to the link between OSA risk and current asthma. Data were obtained from 794 middle-aged participants (mean age, 50 years; 49.8 percent male) in a population-based cohort with available information on OSA risk (defined by a STOP-Bang questionnaire score of at least 3), current asthma and NAS and underwent methacholine bronchial challenge testing.

The authors used regression models to examine the association between OSA risk and current asthma-NAS subgroups and to probe any effect modification by BHR.

OSA risk correlated with NAS with (odds ratio [OR], 2.6, 95 percent confidence interval [CI], 1.3–5.0) or without current asthma (OR, 4.2, 95 percent CI, 1.1–16.1), but not with current asthma in the absence of NAS. BHR correlated with current asthma with (OR, 2.9, 95 percent CI, 1.4–5.9) or without NAS (OR, 3.4, 95 percent CI, 2.0–7.0), but not with NAS in the absence of current asthma. Of note, BHR neither modified nor mediated the associations between OSA risk and current asthma.

“Patients with nocturnal asthma symptoms should be considered for possible OSA,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 5 days ago
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
6 days ago
Testosterone treatment may slightly improve sexual functioning and quality of life in men without underlying organic causes of hypogonadism, but it offers little to no benefit for other common symptoms of ageing, according to a study. In addition, long-term efficacy and safety of this therapy remain unknown.